Compare AbbVie Inc (ABBV) vs Kohl's Corporation (KSS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Kohl's Corporation — how do they compare? AbbVie Inc trades at $253.69 (market cap $449.91B), while Kohl's Corporation trades at $15.86 (market cap $1.90B). The key difference: AbbVie Inc is far larger — about 236.8× Kohl's Corporation's market cap, and Kohl's Corporation pays the higher dividend (2.98%). Which is the better fit depends on your goals.
| ABBV | KSS | |
|---|---|---|
Market Cap | $449.91B | $1.90B |
Sector | Health | Consumer Cyclical |
52-Week High | $261.07 | $24.71 |
52-Week Low | $184.85 | $9.08 |
Enterprise Value | $513.38B | $8.00B |
Dividend Yield | 2.72% | 2.98% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.
The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.
Kohl's (KSS) trades at $16.76, down 7.86% on the day, with the stock showing mixed technical signals amid a broader turnaround effort. The company demonstrates improving fundamentals with recent earnings beats and proprietary brand growth, though revenue continues to decline. Valuation metrics appear attractive with a P/E of 7.1 and P/S of 0.12, while technical indicators show bullish moving averages but neutral oscillators.
Kohl's presents a compelling value opportunity with strong proprietary brand momentum and cost controls, though execution risks remain high amid declining sales and intense retail competition. The stock's current price aligns with analyst consensus targets, suggesting limited near-term upside without clearer evidence of sustainable revenue growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Kohl's Corporation
Kohl's operates 1,165 department stores in 49 states that sell moderately priced private-label and national brand clothing, shoes, accessories, cosmetics, and home furnishings. Most of these stores are in strip centers. Kohl's also operates a large digital sales business. Women's apparel is Kohl's largest category, having generated 27% of its 2021 sales. The retailer, headquartered in Menomonee Falls, Wisconsin, opened its first department store in 1962.
Read more on KSS →
